title: [Treatment of hepatic functional reserve injury after TACE in hepatocellular carcinoma with Chinese herbal medicines].
abstract: OBJECTIVE
  Transcatheter arterial chemoembolization (TACE) has been proved to injure hepatic functional reserve. The current study was designed to evaluate the effect of Chinese herbal medicines in treatment of hepatic functional reserve injury after TACE.
  
  
  METHODS
  Sixty-one advanced hepatocellular carcinoma patients were divided into two groups: groups A (Western medicine combined with Chinese herbal medicine group, n = 30) and group B (Western medicine group, n = 31). Western medicines were used to protect hepatic function and alleviate TACE syndrome in both group A and group B. Invigorating the spleen and activating blood circulation Chinese herbal medicines were added only in group A before and after TACE. Retention rate of Indocyanine green at 15 minutes (ICGR15) was measured in both group A and group B before 1st, 2nd TACE and one month after 2nd TACE respectively.
  
  
  RESULTS
  Hepatic functional reserve before 1st TACE was 11.18% +/- 7.30% in group A and 11.83 +/- 7.18% in group B, (P > 0.05). Hepatic functional reserve before 2nd TACE was 11.69% +/- 5.13% in group A and 16.64 +/- 10.15% in group B, (P < 0.05). Hepatic functional reserve one month after 2nd TACE was 11.53% +/- 5.30% in group A and 19.80 +/- 11.26% in group B, (P < 0.05).
  
  
  CONCLUSIONS
  Invigorating the spleen and activating blood circulation Chinese herbal medicine can prevent hepatic functional reserve injury after TACE.
authors.affiliation: Department of Traditional Chinese Medicine, Cancer Center, Sun Yat-sen University, Guangzhou 510060, P. R. China.
authors.forename: Xun-xian
authors.initials: XX
authors.lastname: Chen
authors.forename: Bei
authors.initials: B
authors.lastname: Zhang
authors.forename: Ya-qi
authors.initials: YQ
authors.lastname: Zhang
authors.forename: Guo-xian
authors.initials: GX
authors.lastname: Hung
authors.forename: Min-shan
authors.initials: MS
authors.lastname: Chen
authors.forename: Rong-ping
authors.initials: RP
authors.lastname: Guo
authors.forename: Xiao-jun
authors.initials: XJ
authors.lastname: Lin
authors.forename: Pei-li
authors.initials: PL
authors.lastname: Hu
authors.forename: Hui-juan
authors.initials: HJ
authors.lastname: Qiu
authors.forename: Bo-ping
authors.initials: BP
authors.lastname: Xu
mesh_terms: D000328:Adult; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000503:physiopathology; D016461:Chemoembolization, Therapeutic / Q000009:adverse effects*; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008099:Liver / Q000187:drug effects / Q000293:injuries / Q000503:physiopathology*; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged
chemical_list: D004365:Drugs, Chinese Herbal